PremiumThe FlyGossamer Bio reports Q4 revenue $9.4M, consensus $7.0M Gossamer Bio Reports Revenue Growth Amid Strategic Collaborations Gossamer Bio reports Q3 EPS (14c), consensus (15c) PremiumThe FlyClosing Bell Movers: Rumble jumps 8% on earnings Gossamer Bio reports Q2 EPS 22c, consensus 23c GOSS Upcoming Earnings Report: What to Expect? PremiumThe FlyGossamer Bio initiated with an Outperform at Oppenheimer Biotech Alert: Searches spiking for these stocks today Aerovate Therapeutics downgraded to Neutral from Buy at Guggenheim 
